Cogent Biosciences, Inc. Deferred Income Tax Expense (Benefit)
Cogent Biosciences, Inc. (COGT) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-17
- Cogent Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- Cogent Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Cogent Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Cogent Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 79 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-17 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-17 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 | |
| 2020-12-31 | $0.00 10-K · filed 2022-03-15 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | |
| 2019-12-31 | $0.00 10-K · filed 2021-03-16 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 | |
| 2017-12-31 | $0.00 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |